title: Whither thiotepa (for patients in the USA)?
authors.affiliation: Department of Neurology, Barrow Neurological Institute, Suite 300, 500 W Thomas Road, Phoenix, AS, 85014, USA. christopherdardis@gmail.com.
authors.forename: Christopher
authors.identifier: http://orcid.org/0000-0002-5798-4747
authors.initials: C
authors.lastname: Dardis
authors.affiliation: Department of Neurology, Barrow Neurological Institute, Suite 300, 500 W Thomas Road, Phoenix, AS, 85014, USA.
authors.forename: Kelly
authors.initials: K
authors.lastname: Milton
authors.affiliation: Department of Neurology, Barrow Neurological Institute, Suite 300, 500 W Thomas Road, Phoenix, AS, 85014, USA.
authors.forename: Lynn
authors.initials: L
authors.lastname: Ashby
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000600:supply & distribution* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy; D013852:Thiotepa / Q000600:supply & distribution* / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
chemical_list: D018906:Antineoplastic Agents, Alkylating; D013852:Thiotepa